Biography
Dr Nat Lenzo is a highly experienced and internationally recognised Nuclear Medicine Physician with more than 25 years’ experience in specialised nuclear oncology.
Dr Lenzo completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Western Australia. He received advanced training in general and nuclear medicine at Fremantle, Sir Charles Gairdner and Royal Perth Hospitals, and subsequently completed a fellowship in nuclear medicine at the University of Michigan. He is a Fellow of the Royal Australian College of Physicians (FRACP) and Australasian Association of Nuclear Medicine Specialists (FAANMS).
In 2015, Dr Lenzo founded Theranostics Australia, the nation’s first private theranostics practice, where he worked as a group clinical director and expanded the field of nuclear oncology globally. He has held notable positions including Head of Nuclear Medicine at Royal Perth Hospital, Head of the Western Australia PET Cyclotron Service at Sir Charles Gairdner Hospital, and Head of General Medicine at Fremantle Hospital. He is also the Founding Director of Cyclowest, a start-up company with a strong focus on patient care and cutting-edge innovative molecular imaging research to help bring the latest diagnostic and therapeutic radiopharmaceuticals to Perth and the Asia-Pacific region.
Alongside his practice at Icon, Dr Lenzo is an adjunct Clinical Professor in Medicine at Curtin University and Notre Dame University Australia and consultant physician at St John of God Hospital Murdoch. He is a Board Member at radiopharmaceutical company, Glytherix, and holds advisory Roles with Telix Pharmaceuticals, Novartis Australia, 3BP, ANSTO and the University of Queensland Centre for Advanced Imaging.
Dr Lenzo maintains a strong interest in clinical research and has co-authored over 60 peer-reviewed publications specialising in molecular imaging and targeted therapies.
He treats at Icon Cancer Centre North Lakes, with a view to begin treating more patients across the eastern seaboard and at Icon’s Singapore locations and beyond.
Publications
Nguyen, H., Hird, K., Cardaci, J., Smith, S., & Lenzo, N. P. (2024). Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes. Molecular diagnosis & therapy, 10.1007/s40291-024-00699-w. Advance online publication.
Lenzo, N., O’Byrne, K., Ngai, S., Meyrick, D., Patel, N., Hayward, C. (2024). Journal of Clinical Oncology 42 (4_suppl), TPS253-TPS253. Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer.
Hawkins, C., Lenzo, N., Gibson, J., Brown, T., Patel, N., Martina, S., Hayward, C. (2024). ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic.
Sathekge, MM., Lawal, IO., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G. (2024). The Lancet Oncology 25 (2), 175-183.Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Lenzo, N. (2024). Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration.